Drug Approval | March 01, 2024
Biocon Biologics secures US market entry date for Bmab 1200
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
_in_Mizushima,_Japan_256_384.jpg)
Contributing to lower risk of potentially carcinogenic nitrosamine impurities in pharmaceuticals
The plant will drive pharmaceutical innovation in the Northeastern India
Academic and Policy Research to get further boost, RIS will bring forth Ayush Service Sector report soon
The contract awarded to Kilitch Estro Biotech PLC entails the supply of pharmaceuticals with an order size amounting to US$ 9.13 million
VeerHealth Care will be raising Rs. 8 crores through bank borrowings
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
Through our research, we aim to ultimately provide new options for our customers to treat life-threatening infections in livestock
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
Subscribe To Our Newsletter & Stay Updated
